Mr. Xue joined Morningside Ventures in 2005, in charge of healthcare related investment activities of Great China region. Michael has engaged in and led many investments in biotech, medtech and healthcare start-ups. He sits on boards of companies including ARK, Zensun, Medtrum, Luqa and Omni Pharmaceutical. Michael Xue holds a MBA degree from Cheung Kong Graduate School of Business, and a M.Sc. degree in organic chemistry from Nankai University.